Computational LNP Delivery Platform

10,000 formulations.
One IND-ready LNP.

Gendelivr's computational screen ranks lipid nanoparticle candidates by hepatocyte transfection efficiency — compressing 18-month delivery optimization to 5.

Request Platform Access See the Science
10,000+ LNP variants
screened/campaign
5 mo avg bench
to IND
~94% prediction accuracy
in vivo outcomes

18 months of bench optimization, condensed to 5. Here's how.

The Platform

Three modules. One IND-ready formulation.

Each module addresses a specific bottleneck in the LNP development pipeline — from initial design space exploration to final IND documentation.

Formulation Engine

Screens 10,000 ionizable lipid and excipient combinations in silico. Our physics-informed model predicts pKa, encapsulation efficiency, and particle size before any bench synthesis.

Explore module

Hit Ranking

Ranks candidates by predicted hepatocyte transfection efficiency vs. cytotoxicity. Top-ranked formulations are exported as prioritized bench-synthesis queues — typically 20–30 candidates from 10,000 screened.

Explore module

IND Workflow

Structures validated formulation data into IND Module 3 format. Generates CMC sections, analytical characterization summaries, and stability assessment documentation.

Explore module
In Action

LNP ranking at a glance

Our ranking engine outputs a scored table of candidate formulations, each annotated with predicted transfection efficiency, cytotoxicity index, and particle stability score. Amber rows indicate top-tier candidates flagged for bench validation.

All data is export-ready: CSV for informatics pipelines, PDF for CMC documentation, JSON for ELN integration.

Request Access Hit Ranking Details
LNP Campaign GDV-2025-08 — Top Results
Rank Formulation ID Ionizable Lipid Transfection % CTX Index Score
01 GDV-F-0042 IL-C8-linDMA 87.3% 0.08 9.82
02 GDV-F-0117 IL-C12-oxDMA 84.1% 0.11 9.56
03 GDV-F-0089 MC3-analog-4 82.7% 0.13 9.34
04 GDV-F-0201 IL-C10-esterDMA 78.4% 0.17 8.91
05 GDV-F-0334 piperazine-C12 76.9% 0.19 8.73
... 9,995 additional formulations ranked
The Biology

Built on rigorous LNP biology

Our computational model incorporates the ApoE-mediated hepatic uptake mechanism, ionizable lipid pKa optimization, and endosomal escape kinetics — grounded in published LNP biology rather than black-box curve fitting.

Every efficiency prediction traces back to a biophysical mechanism. We can tell you why a formulation ranks as it does, not just that it does.

Explore the Science
10,000+ LNP formulation variants
screened per campaign
5 mo average bench-to-IND
delivery optimization
~94% prediction accuracy
on in vivo outcomes
18→5× timeline compression
factor
Who We Work With

Built for gene therapy R&D teams

Senior Scientist, Gene Therapy R&D
The Problem 18-month delivery optimization cycles blocking IND submission timelines. Formulation parameter space too large to explore exhaustively on the bench.
With Gendelivr Reduced LNP screen from 450 bench formulations to 23 validated candidates before animal studies — first-pass predictions within 72 hours of uploading target tissue profile.
Head of Delivery Platform, Gene Therapy R&D
The Problem BD timeline compressed — need to demonstrate hepatic delivery feasibility in weeks, not months. Internal team cannot run 10,000 formulation iterations at bench scale.
With Gendelivr In silico screen identifies top-20 hepatocyte-targeted LNP candidates with predicted ApoE corona profiles and endosomal escape scores — enabling confident go/no-go decisions before animal work.
In Their Words

What gene therapy scientists say

We were staring at a 16-month bench screen before IND. After running Gendelivr's computational campaign against our target tissue profile, we narrowed to 18 candidates in four days. The pKa and encapsulation predictions were consistently within measurement error of our bench results.

Senior Scientist, Gene Therapy R&D — CRISPR therapeutics company

The hepatic targeting model is notably well-calibrated. The ApoE corona prediction correctly ranked our MC3-analog formulations in order of in vivo liver uptake. That kind of mechanistic accuracy is what separates this from generic ML screening tools.

Head of Delivery Platform — gene therapy program within a pharma

Ready to compress your timeline?

Request access to the Gendelivr platform and upload your first target tissue profile. Results within 72 hours.

Request Platform Access Schedule a Technical Call

Boston, MA · [email protected] · +1 (617) 555-0962